Novartis Vaccines and Diagnostics, Inc.

Cambridge, MA 02139

SBIR Award Summary

Total Number of Awards 8
Total Value of Awards $0.0
First Award Date 09/01/87
Most Recent Award Date 09/30/90

Key Personnel

Last Name Name Awards Contact
Steimer Kathelyn S Steimer 2
Barr Philip Jeffreyj Barr 2
Marcus Frank Marcus 1
Spaete Richard R Spaete 2
Van Nest Gary A Van Nest 1

8 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/90 - 03/29/91

We are developing a subunit vaccine directed against human cytomegalovirus (CMV) using recombinant derivatives of viral glycoproteins which are capable of inducing neutralizing antibodies in humans. A candidate antigen for this vaccine is CMV glycoprotein H (gH), which has been shown to induce a strong complement-independent neutralizing respons...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/90 - 05/31/91

Attempts to generate HAV vaccines have been unsuccessful to date due to several factors including poor growth of the virus in tissue culture, absence of in vitro markers of attenuation, and the fact that isolated viral proteins do not display virus neutralizing epitopes. As an alternative to classical killed virus or a attenuated virus vaccine ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/90 - 10/31/90

We will express recombinant forms of human cytomegalovirus (CMV) glycoprotein B for use in the development of a subunit vaccine against CMV. We will use in vitro mutagenesis and other recombinant DNA techniques to generate two forms of glycoprotein B: 1) an uncleaved gB molecule lacking the C-terminal transmembrane and cytoplasmic domain; 2) a...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/89 - 04/30/90

The objective of this proposal is to use genetic engineering methodologies for the development of safe and effective subunit vaccines for preventing infection by human malarial parasites. Plasmodium falciparum and P. vivax, the most common forms of human malaria, are highly prevalent worldwide and cause considerable morbidity and mortality. An ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/89 - 10/31/89

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/88 - 12/31/89

The main objective of this proposal is to utilize genetic engineering methodologies to develop a safe and effective subunit vaccine for preventing infection by the AIDS (Acquired immune deficiency syndrome) retrovirus. AIDS and ARC (AIDS-related complex) are significant causes of morbidity and mortality in the U.S. and on the African continent....

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/88 - 04/30/89

The objective of this proposal is to use genetic engineering methodologies for the development of safe and effective subunit vaccines for preventing infection by human malarial parasites. Plasmodium falciparum and P. vivax, the most common forms of human malaria, are highly prevalent worldwide and cause considerable morbidity and mortality. An ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/87 - 08/31/88

The main objective of this proposal is to utilize genetic engineering methodologies to develop a safe and effective subunit vaccine for preventing infection by the AIDS (Acquired immune deficiency syndrome) retrovirus. AIDS and ARC (AIDS-related complex) are significant causes of morbidity and mortality in the U.S. and on the African continent....